---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-207816"
form_type: "8-K"
ticker: "NUVB"
cik: "0001811063"
company_name: "Nuvation Bio Inc."
filed_at: "2022-08-01T23:59:59+00:00"
generated_at: "2026-06-24T06:36:06.382025+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Nuvation Bio discontinues NUV-422 program due to uveitis safety; cuts 35% of staff

## Summary
- Discontinued NUV-422 clinical program after FDA partial clinical hold due to unpredictable uveitis safety signal.
- Workforce reduction of ~30 employees (35%) expected to save ~$11.8M annually; restructuring charges of ~$5.8M in Q3 2022.
- Cash, cash equivalents and marketable securities of ~$703.8M as of June 30, 2022; cash runway extended through 2028.
- Prioritizing NUV-868 (BD2-selective BET inhibitor) and novel small molecule DDC platform for future development.

## SEC filing metadata
- accession: 0001193125-22-207816
- form_type: 8-K
- ticker: NUVB
- cik: 0001811063
- company_name: Nuvation Bio Inc.
- filed_at: 2022-08-01T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 2.05, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811063/000119312522207816/0001193125-22-207816-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811063/000119312522207816/d379263d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-207816
- JSON: https://secwatch.observer/filing/0001193125-22-207816.json
- Plain text: https://secwatch.observer/filing/0001193125-22-207816.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.